Agenus Inc (AGEN) : Trellus Management Company reduced its stake in Agenus Inc by 18.33% during the most recent quarter end. The investment management company now holds a total of 122,500 shares of Agenus Inc which is valued at $575,750 after selling 27,500 shares in Agenus Inc , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.Agenus Inc makes up approximately 1.30% of Trellus Management Company’s portfolio.
Other Hedge Funds, Including , Simplex Trading reduced its stake in AGEN by selling 12,366 shares or 62.62% in the most recent quarter. The Hedge Fund company now holds 7,382 shares of AGEN which is valued at $34,695.Creative Planning boosted its stake in AGEN in the latest quarter, The investment management firm added 1,762 additional shares and now holds a total of 64,171 shares of Agenus Inc which is valued at $307,379. Benjamin F. Edwards Company sold out all of its stake in AGEN during the most recent quarter. The investment firm sold 5,000 shares of AGEN which is valued $23,950. Bnp Paribas Arbitrage Sa added AGEN to its portfolio by purchasing 2,831 company shares during the most recent quarter which is valued at $13,560.
Agenus Inc opened for trading at $4.51 and hit $4.73 on the upside on Wednesday, eventually ending the session at $4.7, with a gain of 3.75% or 0.17 points. The heightened volatility saw the trading volume jump to 7,40,810 shares. Company has a market cap of $408 M.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform including Retrocyte Display technology which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines and its saponin-based vaccine adjuvants QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages including a series of CPMs in investigational new drug (IND)-enabling studies Prophage Series vaccine a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM) which is a form of brain cancer and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner GlaxoSmithKline (GSK).